Emerging Trends to Drive Mineral And Bone Disorder Treatment Market Growth at 7.1% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Mineral And Bone Disorder Treatment Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size for treatment of mineral and bone disorder has seen substantial growth and is projected to expand from $3.3 billion in 2024 to $3.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.7%. The surge in growth during the historic period can be traced back to factors such as chronic kidney disease, an aging population, increased awareness about mineral and bone disorders, the growing availability of treatment options for these conditions, and a rise in the levels of disposable income.

How Will the Mineral And Bone Disorder Treatment Market Size Evolve and Grow by 2029?
There is a strong expectation of substantial growth in the market size for mineral and bone disorder treatment over the upcoming years. The market is projected to expand to a staggering $4.68 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.1%. The growth during the forecast period is likely due to factors such as the increasing demand for treatments that improve the quality of life, the accelerating trend towards personalized medicine, government's increased healthcare expenditures, and heightened awareness about the importance of diagnosing diseases early. The key trends driving this growth during the forecast period are expected to be progress in medical research, innovations in pharmaceuticals, the rise of digital health, the advent of biologic therapies, and the increasing preference for telehealth and remote monitoring.

View the full report here:
https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

What Drivers Are Propelling the Growth of Mineral And Bone Disorder Treatment Market Forward?
The growth of the mineral and bone disorder treatment market is anticipated to be fueled by the rising elderly populace. We categorize the elderly population as individuals aged 65 or more. Old adults often suffer from muscle and bone mass reduction which leads to weakness and diminished strength. Mineral and bone disorder treatments can combat age-related alterations in muscles, bones, and joints, fortify bones, and slow down the process of bone loss. For example, the UK Parliament's House of Commons Library reported in July 2024 that in 2022, over 12.7 million individuals in the UK, representing 19% of the total population, are expected to be 65 or older. This number is estimated to surge to 22.1 million by 2072, constituting 27% of the populace. Therefore, the expanding elderly populace is fostering the growth of the mineral and bone disorder treatment market. The mineral and bone disorder treatment market's growth is also propelled by an escalating prevalence of chronic kidney diseases. Chronic kidney diseases, or CKD, denotes a gradually advancing medical condition where the kidneys lose their ability to function efficiently over time. Mineral and bone disorder treatments aim to maintain an appropriate mineral balance and preserve bone health in chronic kidney disease patients, thereby reducing complications related to these imbalances. As per a March 2023 report by the National Library of Medicine, a US-based medical library, over 800 million people or 10% of the global population are suffering from chronic kidney diseases, a degenerative disorder. Therefore, the rising prevalence of chronic kidney diseases is fostering the growth of the mineral and bone disorder treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp

Which Emerging Trends Are Transforming the Mineral And Bone Disorder Treatment Market in 2025?
Major firms in the mineral and bone disorder treatment market are concentrating on the development and approval of new products to enhance their market standing. The increasing numbers of aging citizens and chronic kidney disease incidents, such as TYMLOS (abaloparatide) - a synthetic version of the human parathyroid hormone, have led to the rise in the approval of drugs for mineral and bone. To illustrate, in December 2022, Radius Health Inc., an American biopharmaceutical company, obtained approval for TYMLOS (abaloparatide), a parathyroid hormone-related peptide analog [PTHrP(1-34)], intended for use in magnifying bone density in men with high fracture risk osteoporosis. This drug operates as a bone anabolic agent, selectively triggering the parathyroid hormone 1 receptor (PTH1R) in osteoblasts and osteocytes, resulting in enhanced bone formation and density.

What Are the Key Segments in the Mineral And Bone Disorder Treatment Market?
The mineral and bone disorder treatment market covered in this report is segmented -

1) By Treatment: Diet, Nutrition, Medication, s, Dialysis
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Diet: Calcium-Rich Foods, Vitamin D-Enriched Foods, Phosphorus-Rich Foods
2) By Nutrition: Nutritional Counseling, Fortified Food Products, Meal Replacement Programs
3) By Medication: Bisphosphonates, Hormonal Therapies, RANK Ligand Inhibitors
4) By s: Calcium s, Vitamin D s, Multivitamin s
5) By Dialysis: Hemodialysis, Peritoneal Dialysis, Continuous Renal Replacement Therapy (CRRT)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12956&type=smp

Who Are the Key Players Shaping the Mineral And Bone Disorder Treatment Market's Competitive Landscape?
Major companies operating in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.

What Geographic Markets Are Powering Growth in the Mineral And Bone Disorder Treatment Market?
North America was the largest region in the mineral and bone disorder treatment market in 2024. The regions covered in mineral and bone disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12956

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.